A Mixed-Methods Investigation of HIV Treatment and Prevention Among Individuals with Methamphetamine Use Disorder
Learning More about HIV Treatment and Prevention among People with Methamphetamine Use Disorder
Sponsor: Merck
Enrolling: Male and Female Patients
IRB Number: 7933
Contact: Jermaine Jones PhD: 646-774-6113 / jermaine.jones@nyspi.columbia.edu
Additional Study Information: This proposal will utilize a dual approach, studying methamphetamine users who are HIV-positive (Study A), and those who are HIV negative (Study B). Study A (N=125) is a quantitative investigation. Various self-report and clinician-administered inventories will be given to investigate the frequency and severity of co-morbidities related to methamphetamine abuse that may impact NNRTI-based HIV-1 treatment. Among methamphetamine users who are HIV negative, maintaining this status is of immense public health importance. Pre-exposure prophylaxis (PrEP), using antiretroviral drugs, has proven effective in other high-risk populations. Yet, adherence to a daily dosing regimen may be a major hurdle for people with methamphetamine use disorder. Long-acting PrEP formulations may be better suited for this population. Thus, the second aim of the proposal will be to assess participant attitudes concerning HIV prevention that will inform investigators about the feasibility and acceptability of pharmacological HIV prevention. Study B will consist of a semi-structured qualitative interview (N=30) designed to explore previous experiences and attitudes concerning HIV prevention.
This study is closed
Jermaine Jones, PhD
Do You Qualify?
Do you currently use methamphetamine? Yes No
Are you between the ages of 18-55? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jermaine Jones PhD